Back to Search
Start Over
A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan
- Source :
- European Heart Journal, 36(47), 3332-3342. Oxford University Press
- Publication Year :
- 2015
-
Abstract
- Aims Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown. Methods and results ABSORB Japan was a single-blind, multicentre, active-controlled, randomized trial designed to support regulatory approval of the Absorb BVS in Japan. Eligible patients with one or two de novo lesions in different epicardial vessels were randomized at 38 Japanese sites in a 2:1 ratio to Absorb BVS vs. cobalt-chromium everolimus-eluting stents (CoCr-EESs). The primary endpoint was target lesion failure [TLF: a composite of cardiac death, myocardial infarction attributable to target vessel, or ischaemia-driven target lesion revascularization (ID-TLR)] at 12 months, powered for non-inferiority. The major secondary endpoint was angiographic in-segment late lumen loss (LLL) at 13 months. A total of 400 patients were randomized to BVSs (266 patients and 275 lesions) or CoCr-EESs (134 patients and 137 lesions). TLF through 12 months was 4.2% with BVSs and 3.8% with CoCr-EESs [difference (upper one-sided 95% confidence limit) = 0.39% (3.95%); P non-inferiority < 0.0001]. Definite/probable stent/scaffold thrombosis at 12 months occurred in 1.5% of the patients with both devices ( P = 1.0), and ID-TLR for restenosis was infrequent (1.1% with BVSs and 1.5% with CoCr-EESs, P = 1.0). With 96.0% angiographic follow-up, in-segment LLL at 13 months was 0.13 ± 0.30 mm with BVSs and 0.12 ± 0.32 mm with CoCr-EESs [difference (upper one-sided 95% confidence limit) = 0.01 (0.07); P non-inferiority < 0.0001). Conclusion In the ABSORB Japan randomized trial, 12-month clinical and 13-month angiographic outcomes of BVSs were comparable to CoCr-EESs. Clinical registration ClinicalTrials.gov, number [NCT01844284][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01844284&atom=%2Fehj%2Fearly%2F2015%2F08%2F28%2Feurheartj.ehv435.atom
- Subjects :
- Male
Target lesion
medicine.medical_specialty
medicine.medical_treatment
Operative Time
Myocardial Infarction
Coronary Artery Disease
Prosthesis Design
Revascularization
Percutaneous Coronary Intervention
Restenosis
Absorbable Implants
Coronary stent
Myocardial Revascularization
medicine
Clinical endpoint
Humans
Single-Blind Method
Everolimus
Myocardial infarction
Aged
Tissue Scaffolds
business.industry
Graft Occlusion, Vascular
Stent
Drug-Eluting Stents
medicine.disease
Surgery
Treatment Outcome
Female
Cardiology and Cardiovascular Medicine
business
Immunosuppressive Agents
medicine.drug
Subjects
Details
- ISSN :
- 0195668X
- Database :
- OpenAIRE
- Journal :
- European Heart Journal, 36(47), 3332-3342. Oxford University Press
- Accession number :
- edsair.doi.dedup.....421b41eb7ed9d6446ee4c3869c56bd83